恩替卡韦治疗乙肝肝硬化患者的临床疗效

Clinical Efficacy of Entecavir in the Treatment of Patients With Hepatitis B Cirrhosis

目的探究恩替卡韦(ETV)与阿德福韦酯(ADV)对乙肝肝硬化患者肝纤维化、甲状腺激素的影响比较。方法选取2014年6月-2019年6月本院收治的乙肝肝硬化患者80例,按随机数表法分为两组,ETV组与ADV组各40例。ETV组进行常规治疗加服恩替卡韦治疗,ADV组则在常规治疗上加服阿德福韦酯治疗,两组均干预48周。观察比较两组患者治疗48周肝纤维化指标以及甲状腺激素功能变化情况。结果治疗后,ETV组的HA、LN、PCⅢ及ⅣC改善的程度明显比ADV组更好(P <0.05);ETV组的LSM下降程度明显优于ADV组(P <0.05);ETV组T3、T4、FT3、FT4水平明显高于ADV组(P<0.05),而TSH水平明显要比ADV组低(P <0.05)。结论对于乙肝肝硬化患者来说,采用恩替卡韦进行治疗更能改善患者的肝纤维化以及甲状腺激素功能。

Objective To investigate the effects of entecavir(ETV) and adefovir dipivoxil(ADV) on liver fibrosis and thyroid hormone in patients with hepatitis B cirrhosis. Methods From June 2014 to June 2019, 80 patients with hepatitis B liver cirrhosis were divided into two groups according to the random number table method, and 40 cases in the ETV group and the ADV group. The ETV group was treated with conventional therapy plus Entecavir, and the ADV group was treated with conventional therapy plus adefovir dipivoxil, both in 48 weeks. The changes of liver fibrosis index and thyroid hormone function in 48 weeks were observed in two groups. Results After treatment, the improvement of HA, LN, PC Ⅲ and Ⅳ C in ETV group was significantly better than that in ADV group(P<0.05). The decrease of LSM in ETV group was significantly better than that in ADV group(P<0.05). The levels of T3, T4, FT3 and FT4 in ETV group were significantly higher than those in ADV group(P<0.05), while the level of TSH was significantly lower than that in ADV group(P<0.05). Conclusion For patients with hepatitis B cirrhosis, treatment with Entecavir can improve the liver fibrosis and thyroid hormone function of patients.